Inavolisib plus eribulin for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is for people with advanced triple-negative breast cancer that has a specific gene change (PIK3CA). It tests a combination of two drugs (inavolisib and eribulin) to see if they can help shrink or control the cancer. If you've had prior treatment but it didn't work well enough, you may be a candidate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have breast cancer that has spread or cannot be removed with surgery.
- Your cancer is triple-negative and has a specific gene change (PIK3CA) that the trial drug targets.
- You have already had at least one round of chemotherapy for advanced breast cancer.
- You are in generally good health (able to take care of yourself, but not necessarily fully active).
- You can provide a piece of your tumor (from a biopsy or stored sample) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
This study looks at how well a drug called inavolisib works when combined with hormone therapy for people with a certain type of advanced breast cancer that has a specific gene change (PIK3CA). It aims to see if this treatment helps control the cancer in real-world settings.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
This trial tests a combination of three targeted therapies (inavolisib, ribociclib, and fulvestrant) in people with a specific type of advanced breast cancer that has a PIK3CA genetic change. The goal is to see if this new combination can shrink tumors or slow cancer growth, potentially offering a new option before other treatments are needed.
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.